WO2007020085A3 - Compositions containing taxane derivatives for intravenous injection - Google Patents

Compositions containing taxane derivatives for intravenous injection Download PDF

Info

Publication number
WO2007020085A3
WO2007020085A3 PCT/EP2006/008116 EP2006008116W WO2007020085A3 WO 2007020085 A3 WO2007020085 A3 WO 2007020085A3 EP 2006008116 W EP2006008116 W EP 2006008116W WO 2007020085 A3 WO2007020085 A3 WO 2007020085A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
intravenous injection
taxane derivatives
containing taxane
derivatives
Prior art date
Application number
PCT/EP2006/008116
Other languages
German (de)
French (fr)
Other versions
WO2007020085A2 (en
Inventor
Cristian Ramiro Franco
Nikolaus Kofler
Elsa Elena Mendioroz
Silvia E S Dominguez
Original Assignee
Sandoz Ag
Cristian Ramiro Franco
Nikolaus Kofler
Elsa Elena Mendioroz
Silvia E S Dominguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag, Cristian Ramiro Franco, Nikolaus Kofler, Elsa Elena Mendioroz, Silvia E S Dominguez filed Critical Sandoz Ag
Publication of WO2007020085A2 publication Critical patent/WO2007020085A2/en
Publication of WO2007020085A3 publication Critical patent/WO2007020085A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Novel taxane derivatives based compositions comprising a solution of such derivatives in a surfactant. These compositions can be used to prepare perfusion solutions.
PCT/EP2006/008116 2005-08-19 2006-08-17 Compositions containing taxane derivatives for intravenous injection WO2007020085A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0517092A GB0517092D0 (en) 2005-08-19 2005-08-19 New compositions containing taxane derivatives
GB0517092.3 2005-08-19

Publications (2)

Publication Number Publication Date
WO2007020085A2 WO2007020085A2 (en) 2007-02-22
WO2007020085A3 true WO2007020085A3 (en) 2007-11-08

Family

ID=35098012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008116 WO2007020085A2 (en) 2005-08-19 2006-08-17 Compositions containing taxane derivatives for intravenous injection

Country Status (3)

Country Link
AR (1) AR056465A1 (en)
GB (1) GB0517092D0 (en)
WO (1) WO2007020085A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US8969310B2 (en) 2005-07-15 2015-03-03 Angiochem Inc. Potentiation of anticancer agents
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527634T3 (en) 2005-02-18 2015-01-27 Angiochem Inc. Aprotinin polypeptides to transport a compound through the blood-brain barrier
WO2007134354A1 (en) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmaceutical formulation
CN101327206B (en) * 2007-06-22 2011-07-20 成都市益斯生物科技有限公司 Docetaxel injection and preparation method thereof
AR063111A1 (en) * 2007-10-03 2008-12-30 Eriochem Sa A PHARMACEUTICAL FORMULATION OF TAXANO
KR101053780B1 (en) * 2008-02-29 2011-08-02 동아제약주식회사 Single liquid stable pharmaceutical composition containing docetaxel
US9180088B2 (en) 2008-03-07 2015-11-10 Scidose, Llc Fulvestrant formulations
MX355683B (en) * 2008-04-18 2018-04-26 Angiochem Inc Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use.
ES2344674B1 (en) 2008-08-07 2011-06-29 Gp Pharm, S.A. INJECTABLE PHARMACEUTICAL COMPOSITION OF TAXANOS.
AU2009322043A1 (en) 2008-12-05 2011-07-07 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CA2747220A1 (en) 2008-12-17 2010-06-24 Richard Beliveau Membrane type-1 matrix metalloprotein inhibitors and uses thereof
WO2012092421A2 (en) * 2010-12-30 2012-07-05 Surmodics, Inc. Composition for intravascular delivery of therapeutic composition
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
EP2875814B1 (en) * 2012-07-19 2018-08-22 FUJIFILM Corporation Liquid composition containing taxane-based active ingredient, process for producing same, and liquid medicinal preparation
US9012665B2 (en) 2012-07-31 2015-04-21 Yung Shin Pharm. Ind. Co., Ltd. Amorphous cabazitaxel
US9198969B2 (en) 2012-08-15 2015-12-01 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
JP6285725B2 (en) * 2014-01-16 2018-02-28 ナガセ医薬品株式会社 Ethanol-free docetaxel pharmaceutical composition
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5438072A (en) * 1992-12-02 1995-08-01 Rhone-Poulenc Rorer S.A. Taxoid-based compositions
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2005097105A1 (en) * 2004-04-09 2005-10-20 Ung-Kil Jee Injectable composition for the treatment of cancers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403858A (en) * 1991-07-08 1995-04-04 Rhone-Poulenc Rorer, S.A. New compositions containing taxane derivatives
US5438072A (en) * 1992-12-02 1995-08-01 Rhone-Poulenc Rorer S.A. Taxoid-based compositions
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
WO2002043765A2 (en) * 2000-11-28 2002-06-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
WO2005097105A1 (en) * 2004-04-09 2005-10-20 Ung-Kil Jee Injectable composition for the treatment of cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; August 2005 (2005-08-01), JEON IL-SOON ET AL: "Preparation and evaluation of paclitaxel nano-particle delivery system for parenteral formulations", XP002429519, Database accession no. PREV200600042517 *
YAKHAK HOEJI, vol. 49, no. 4, August 2005 (2005-08-01), pages 268 - 274, ISSN: 0377-9556 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9221867B2 (en) 2003-01-06 2015-12-29 Angiochem Inc. Method for transporting a compound across the blood-brain barrier
US8969310B2 (en) 2005-07-15 2015-03-03 Angiochem Inc. Potentiation of anticancer agents
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid

Also Published As

Publication number Publication date
GB0517092D0 (en) 2005-09-28
AR056465A1 (en) 2007-10-10
WO2007020085A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2007020085A3 (en) Compositions containing taxane derivatives for intravenous injection
WO2008013840A3 (en) Erastin analogs and uses thereof
MX2009006598A (en) Sulfonamide derivatives as liver carnitine palmitoyl transferase (l-cptl ).
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
ME02015B (en) Pharmaceutical compositions with (1S)-1,5-anhydro-1-[5- (4-ethoxybenzyl)-2- methoxy-4-methylphenyl]-1-thio-D-glucitol and an insulin secretagogue
MX337166B (en) Topical composition containing ibuprofen.
WO2008081096A3 (en) Quinolinyl derivatives, method for preparing same, pharmaceutic compositions containing same, and use thereof as hypoglycemiant and hypolipemiant agents
UA94052C2 (en) Pyridazine derivatives
MY140841A (en) Indozolone derivatives as 11b-hsd1 inhibitors
WO2010003133A3 (en) Cdk modulators
WO2008021927A3 (en) Hepatitis c virus inhibitors
TW200730511A (en) Chroman compounds
MX2010005824A (en) Aminothiazole derivatives.
MX2007003913A (en) Alkil-pyridines as 11-beta inhibitors for diabetes.
WO2007025880A3 (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
WO2009040289A3 (en) Biaryl sulfonamide derivatives
DE502005008631D1 (en) DERMATOLOGICAL PREPARATIONS
MX2008016426A (en) Alkyl-pyridazine derivatives as inhibitors of 11 beta hydroxysteroid dehydrogenase type 1(11b-hsd 1).
IN2012DN03337A (en)
TW200730510A (en) Chroman compounds
PL2021002T3 (en) Pharmaceutical composition comprising olmesartan medoxomil
WO2007017585A3 (en) Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds
DOP2010000329A (en) RENINE INHIBITORS
HK1146710A1 (en) Radiopharmaceutical composition
MX2009003169A (en) Sulfonamide derivatives.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06776920

Country of ref document: EP

Kind code of ref document: A2